
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals Inc. has experienced significant revenue growth, with LIVMARLI sales reaching $88.1 million in Q2 2025, reflecting an impressive 87% increase year-over-year. The company has adjusted its 2025 revenue guidance upward to a range of $490 million to $510 million, demonstrating robust commercial momentum fueled by the rising adoption of LIVMARLI in treating Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Additionally, the total revenues for Q2 2025 amounted to $127.8 million, marking a 64% year-over-year growth, which reinforces a positive outlook for the company's financial performance.
Bears say
Mirum Pharmaceuticals faces significant commercial risks due to its dependence on method of use and formulation patent coverage for maralixibat, lacking robust composition of matter patent protection. The company's revenue is in an early growth phase, and unexpected competition or slower sales growth could hinder its ability to achieve profitability. Compounding these challenges, the presence of multiple competing ASBT inhibitors in development, along with the company's recent financial losses from the termination of a revenue interest purchase agreement, further contributes to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares